Oncofap News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Oncofap. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Oncofap Today - Breaking & Trending Today

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP)

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP) Translational studies performed at the European Institute ....

Mary Jane Elliott , Davide Salvi , Christian Lizak , Dario Neri , University Hospital , Nuclear Medicine , Italian Stock Exchange , European Journal Of Nuclear Medicine , Department Of Nuclear Medicine University , European Institute For Molecular Imaging , Consilium Strategic Communications , European Institute , Molecular Imaging , Senn Chemicals , European Journal , Chief Executive Officer , Molecular Imagingand , Activation Protein , Proc Natl Acad Sci United States , Italian Stock , Emanuele Puca , Investor Relations , Strategic Communications , Jane Elliott ,

Philogen S.p.A.: Philogen Announces Publication of Best-in-Class FAP-Targeting Small Molecule Ligand (OncoFAP) in PNAS

Philogen S.p.A.: Philogen Announces Publication of Best-in-Class FAP-Targeting Small Molecule Ligand (OncoFAP) in PNAS
(i) Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs - (ii) OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer
SIENA, ITALY / ACCESSWIRE / April 12, 2021 / Philogen S.p.A., a listed clinical-stage biotechnology company focused on the development of innovative medicines based on tumor targeting antibodies and small molecule ligands, is pleased to announce a publication describing the development and the
in vivo characterization of OncoFAP, a best-in-class FAP-targeting small molecule for applications in cancer and inflammation. The paper entitled An Ultra-High Affinity Small Organic Ligand of Fibroblast Activation Protein for Tumor Targeting Applications was published in the peer-reviewed journal ....

Christian Lizak , Dario Neri , Emanuele Puca , Italian Stock Exchange , Business Development , Ultra High Affinity Small Organic Ligand , Fibroblast Activation Protein , Tumor Targeting , Activation Protein , Chief Executive Officer , Italian Stock , Investor Relations , டாரியோ நெறி , இத்தாலிய ஸ்டாக் பரிமாற்றம் , வணிக வளர்ச்சி , ஃபைப்ரோபிளாஸ்ட் செயல்படுத்தல் ப்ரோடீந் , தலைமை நிர்வாகி அதிகாரி , இத்தாலிய ஸ்டாக் , முதலீட்டாளர் உறவுகள் ,